On June 25, 2020, the clinical trial application (ind) submitted by Shandong Xinchuang Biotechnology Co., Ltd. was accepted by nmpa. This product is a new class 1 biological product developed by our company. It is also the first bacterial oncolytic drug to be accepted by ind in the w...
Shandong Xinchuang Biotechnology Co., Ltd. has recently received the notice on the project initiation of the 2019 annual implementation plan of major new drug creation science and technology major project (health science special letter (2019) No. 764) issued by the medical and Health S...
According to the requirements of the notice on the selection of "top 10", "top 10 independent innovation" and "top 10 leaders" of Shandong gazelle enterprises (Lu'an Ling Qi Chu Zi [2019] No. 3), our company was finally awarded the "independent" of Shandong gazelle enterprises after the...
Scientific and technological innovation has made great achievements. On October 14, the final of the 8th China Innovation and entrepreneurship competition in biomedical industry, as the first national competition, ushered in the final peak battle in Guangzhou. The contestants who are...
